Table 2.
Cancer cell lines encompassed in the NCI-60 panel with their weights calculated based on lower and upper outlier frequency in each of the predictive set’s groups, sorted by represented tissue.
Cell No. | Cell Line | Tumoral Tissue Type | Cell line Weight Factors | Cell No. | Cell Line | Tumoral Tissue Type | Cell line Weight Factors | ||
---|---|---|---|---|---|---|---|---|---|
Upper Outliers | Lower Outliers | Upper Outliers | Lower Outliers | ||||||
1 | CCRF-CEM | Leukemia | −4.44 | 0.00 | 31 | M14 | Melanoma | 5.56 | −2.50 |
2 | HL-60(TB) | Leukemia | −20.00 | 5.56 | 32 | MDA-MB-435 | Melanoma | 3.06 | 0.00 |
3 | K-562 | Leukemia | 11.67 | 11.11 | 33 | SK-MEL-2 | Melanoma | 1.81 | −1.25 |
4 | MOLT-4 | Leukemia | −6.94 | −1.25 | 34 | SK-MEL-28 | Melanoma | 11.11 | −3.75 |
5 | RPMI-8226 | Leukemia | −1.94 | 5.56 | 35 | SK-MEL-5 | Melanoma | 3.06 | 0.00 |
6 | SR | Leukemia | −6.39 | 5.56 | 36 | UACC-257 | Melanoma | 1.81 | −2.50 |
7 | A549/ATCC | NSCLC | −1.25 | −1.25 | 37 | UACC-62 | Melanoma | 1.81 | −1.25 |
8 | EKVX | NSCLC | 27.78 | −6.25 | 38 | IGROV1 | Ovarian | 1.81 | −1.25 |
9 | HOP-62 | NSCLC | 0.00 | 4.31 | 39 | OVCAR-3 | Ovarian | 0.00 | 3.06 |
10 | HOP-92 | NSCLC | 8.61 | −3.75 | 40 | OVCAR-4 | Ovarian | −1.25 | −7.50 |
11 | NCI-H226 | NSCLC | 11.11 | 4.31 | 41 | OVCAR-5 | Ovarian | 5.56 | −2.50 |
12 | NCI-H23 | NSCLC | −1.25 | −1.25 | 42 | OVCAR-8 | Ovarian | 0.00 | −1.25 |
13 | NCI-H322M | NSCLC | 27.78 | −5.00 | 43 | NCI/ADR-RES | Ovarian | −1.25 | −14.44 |
14 | NCI-H460 | NSCLC | −10.00 | −1.25 | 44 | SK-OV-3 | Ovarian | 9.86 | 9.86 |
15 | NCI-H522 | NSCLC | 1.81 | 0.00 | 45 | 786-0 | Renal | −3.75 | 4.31 |
16 | COLO 205 | Colon | 5.56 | −1.25 | 46 | A498 | Renal | 24.03 | 4.31 |
17 | HCC-2998 | Colon | −2.50 | −1.25 | 47 | ACHN | Renal | 15.42 | −5.00 |
18 | HCT-116 | Colon | 4.31 | 4.31 | 48 | CAKI-1 | Renal | 17.22 | −7.50 |
19 | HCT-15 | Colon | −2.50 | −7.50 | 49 | RXF 393 | Renal | 4.31 | 0.00 |
20 | HT29 | Colon | 9.86 | 0.00 | 50 | SN12C | Renal | 0.00 | −1.25 |
21 | KM12 | Colon | 16.67 | 4.31 | 51 | TK-10 | Renal | 16.67 | −6.25 |
22 | SW-620 | Colon | 0.00 | 5.56 | 52 | UO-31 | Renal | 3.06 | −8.75 |
23 | SF-268 | CNS | 0.00 | 0.00 | 53 | PC-3 | Prostate | −1.25 | −2.50 |
24 | SF-295 | CNS | −1.25 | 0.00 | 54 | DU-145 | Prostate | −2.50 | −1.25 |
25 | SF-539 | CNS | 4.31 | 5.56 | 55 | MCF7 | Breast | −2.50 | 0.00 |
26 | SNB-19 | CNS | 0.00 | −0.69 | 56 | MDA-MB-231/ATCC | Breast | −1.25 | −5.00 |
27 | SNB-75 | CNS | 6.11 | −1.25 | 57 | MDA-MB-468 | Breast | −3.75 | 0.00 |
28 | U251 | CNS | −1.25 | 5.56 | 58 | HS 578T | Breast | 7.36 | −2.50 |
29 | LOX IMVI | Melanoma | −3.75 | 0.00 | 59 | BT-549 | Breast | 1.81 | −3.75 |
30 | MALME-3M | Melanoma | 5.56 | −1.25 | 60 | T-47D | Breast | −3.75 | 1.81 |
NSCLC = non-small cell lung cancer; CNS = central nervous system; NCI-60 = National Cancer Institute’s previously tested compounds on 60 tumoral cell lines.